Kinetics of anti-SARS-CoV-2 IgG in saliva and serum post infection, and subsequent vaccination in South Africa.

Background: Understanding mucosal immune response to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, and its correlation to systemic responses could improve vaccine development. There is limited data on mucosal and systemic antibody responses to SARS-CoV-2 infection and vaccination in African populations. Objective: This study assessed serum and saliva antibody ratios in a cohort of SARS-CoV-2 infected and vaccinated participants followed up for 12 months. Methods: This longitudinal study comprised of 67 SARS-CoV-2, PCR-confirmed participants who were recruited as part of a COVID-19 Point of Care Study, between January 2021 and September 2022. For this analysis, 254 serum and 214 saliva samples (205 of which were matched), were collected at baseline, 6, 9, and 12 months. Antibodies against Spike (S) and nucleocapsid (N) SARS-CoV-2 were assessed by in-house Luminex assay. Results: Serum and saliva anti-S IgG from were detected for up to 12 months in majority of participants (93.5% and 90%), regardless of vaccination status. There was a concordance between paired serum and saliva antibody in 80.5% anti-S IgG and 41.7% anti-N IgG of samples. There was a weak but significant correlation between the matched serum and saliva samples ( Conclusion: This study reports the correlation of the anti-S and anti-N IgG responses in serum and saliva following SARS-CoV-2 infection and subsequent vaccination in low-middle income setting. Furthermore, high breakthroughs and reinfection were reported. What this study adds: The study findings are consistent with those from high-income settings, supporting correlation between systemic and mucosal immunity and booster vaccination as a long-term strategy to control SARS-CoV-2.